Mastopathia cystica chronica im Hinblick auf krebsige Entartung

Zusammenfassung Als Beitrag zur Frage eines Überganges der Cystenmamma in Carcinom werden in der vorliegenden Arbeit 381 Fälle mit klinisch einwandfrei cystischen Veränderungen der Brustdrüse aus der Chirurgischen Universitätsklinik Jena der Jahre 1920–1946 zusammengestellt unddie histologisch bewiesenen Fälle (169) zu Besprechungen herangezogen. Dabei zeigte sich, daßin 7,1% der Fälle die Mastopathia cystica einenKrebs oder krebsartige Veränderungen aufweist. Nach diesem Häufigkeitsverhältnis können wir diese Erkrankung nicht als Präcarcinomatose oder als Erkrankung, auf deren Boden sich ein Krebs prädisponiert entwickelt, ansprechen. Die Tatsache aber allein der Krebsentwicklung mahnt zur Vorsicht und weist die damit sich ergebende Behandlung, die kurz aufgezeichnet wird. Nachuntersuchungen und Anfragen bestätigen das gefundene Ergebnis.     

Studie über die Aetiologie und Pathogenese der sogenannten generalisirten Vaccine bei Individuen mit vorher gesunder oder kranker Haut

Ohne ZusammenfassungHiezu Taf. I–V.     

Ueber die verschliessung des Schlundes beim Sprechen

Ohne ZusammenfassungHierzu Taf. I–III.Anmerkung des Herausgebers. Diese Abhandlung ist vor dem Erscheinen der neuesten Schrift des Herrn v. Luschka über den Schlundkopf eingesendet worden.     

Ueber die vasomotorischen Wirkungen des Nervus vagus,laryngeus und sympathicus

Ohne Zusammenfassung     

Spontane Heilung einer Hydrocele unter dem Einfluss von Variola

Ohne Zusammenfassung     

Apheresis Technologies: An International Perspective

Abstract: The developments in apheresis techniques and their clinical applications world-wide are technologically driven. In the past, apheresis survey statistics have highlighted both the differences by region in clinical practice and in the types of technologies utilized. Such differences have provided a basis for the scientific and clinical assessments of these apheresis technologies and their clinical outcomes and have stimulated the marketing and business development of new technologies world-wide. A review of the regional practices and technologies utilized provides a perspective on the future role of apheresis and its developments in clinical practice. While technology is a driving force for the development of new techniques for clinical practice, it is not the only market force. For technology introduction, several other important issues need to be considered. Regulations at the local and, most importantly, the federal level impact the timing for new technology introduction. Reimbursement by healthcare payers is critically important from the initiation of the development of a technology through its clinical use. Clinical trials are critically important to show the safety and clinical- and cost-effectiveness of the technology in order for payers to provide reimbursement for its use, but these trials are sometimes long and costly. Research funding availability at the governmental and commercial levels critically impacts new technology investigation and its introduction. Apheresis technology developments offer new hopes and promises for the clinical team; however, their development, introduction, and utilization will be influenced by the prevailing market forces.     

Expression of cell-matrix molecules and integrin receptors in human liver grafts during chronic rejection

Abstract The inflammatory response of immune cells to target cells and cell-matrix molecules is regulated by several receptor-ligand molecules. As fibrosis develops in ongoing chronic rejection after liver transplantation, it is of interest to analyze patterns of integrin receptors and cell-matrix molecules in order to study the relation between immune cells and the stromal and parenchymal cells. In the present study, we demonstrated the expression of these molecules in chronic rejected human liver grafts using immunohistochemical techniques. The results showed a differential expression and induction of integrin receptors and cell-matrix molecules on resident liver cells, especially on sinusoids, reflecting a state of chronic inflammation and a specific interaction between integrin receptors and cell-matrix molecules. The patterns of induced integrin receptors on graft-infiltrating cells was closely related to the local production of cell-matrix molecules and reflected the final sequence of a stepwise progress of the inflammatory reaction.     

Hyponatremic coma under oxcarbazepine therapy.

Oxcarbazepine (OXC) is considered to be a promising new antiepileptic drug with similar efficacy and better tolerability compared to carbamazepine (CBZ). However, hyponatremia is supposed to occur even more often than with CBZ. We report on a patient who developed hyponatremic coma under OXC with a serum sodium level of 115 mmol/l, the second published case of OXC-induced hyponatremia with serious clinical adverse effects.     

Bromide treatment of pharmaco-resistant epilepsies with generalized tonic-clonic seizures: a clinical study.

In a retrospective controlled clinical study we investigated the efficacy of bromides (BR) as to the frequency of generalized tonic-clonic seizures (GTCS) as a monotherapy (n = 5) or combined with other antiepileptic drugs (AEDs) (n = 55), and compared the results statistically with those achieved with a treatment based on phenobarbitone (PB) and/or phenytoin (PHT) in a very similar group of another 60 patients. All patients treated with BR had previously proved to be pharmaco-resistant. In most of the cases the epilepsies were based on early cerebral lesions, and were partly associated with severe mental and physical handicaps. Most of the patients were between three and 14 years old. The percentage of responders was 58%, which means a reduction in the GTCS-frequency of more than 50%. The positive result was observed for 28 months on the average. 27% of all patients became free of GTCS for 18 months on the average (range, 44 days to 62 months), and 32% were improved (reduction in GTCS-frequency of more than 50% while not GTCS-free) for nearly three years on the average (range, 79 days to 110 months). Compared to PHT or PB, BR were slightly more efficient and similarly tolerable, but no statistically significant difference was seen (48% responders in the control group versus 58% responders in the BR-group). Thus, the statistical correlation with competitive therapies confirmed the good efficacy of BR against GTCS, which was previously demonstrated by clinical tests without control studies. We recommended BR in the case of every pharmaco-resistant epilepsy with GTCS as a therapeutic alternative.